Towards diagnosis of minimal residual disease
Liquid biopsies are fast making their mark as a diagnostic test for minimal residual disease (MRD), providing guidance on how to tailor treatment for early-stage cancers
Liquid biopsies are fast making their mark as a diagnostic test for minimal residual disease (MRD), providing guidance on how to tailor treatment for early-stage cancers
At ESMO 2019, early clinical data from two studies show the promise of this new generation of treatments although not yet practice-changing
Results from the monarcHER and KATE2 trials presented
Updated results from the ESMO Women for Oncology study monitoring the representation of women at major national and international congresses and societies
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.